RICERCA ITALIANA     

FIRB simili:

• 1 - Approcci combinati di terapia genica nel trattamento del glioblastoma
• 2 - Metodologie Innovative di Risonanza Magnetica (RM) in Patologie Tumorali e Cardiovascolari
• 3 - Molecole innovative ad attività antiflogistica ed antitumorale prodotte con metodologie chimiche avanzate
• 4 - BILANCIO OSPITE-TUMORE NELLA TERAPIA MEDICA DELLE NEOPLASIE: RUOLO DI NF-kB
• 5 - Riconoscimento molecolare e funzionalità cellulare
• 6 - Meccanismi di regolazione dello sviluppo del sistema nervoso e del differenziamento neurale (PRONEURO)
• 7 - Modelli transgenici per malattie ad eziologia complessa
• 8 - Studio dell'identità cellulare e dei meccanismi di differenziazione cellulare nell'era della postegnomica utilizzando tre situazioni paradigmatiche: la mammella, l'osso e i linfociti
• 9 - Modulazione razionale dell'attività antitumorale di farmaci "classici" tramite intervento selettivo su specifiche cascate regolatorie
• 10 - Metodologie per l'individuazione e lo sviluppo di molecole in grado di interferire specificamente con bersagli critici per la terapia di malattie

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze chimiche
  • CHIMICA FARMACEUTICA
• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA GENERALE
  • ONCOLOGIA MEDICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Piemonte

Bibliografia

1. van Herpen CM, De Mulder PH. Locoregional immunotherapy in cancer patients: review of clinical studies. Ann Oncol. 11(10):1229-39, 2000
2. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Arterioscler Thomb Vasc Biol 17:1193-1202,1997.
3 Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1:27-31, 1995.
3 Gasparini G,Harris AL:Clinical importance of the determination of tumor angiogenesis in breast carcinoma :much more than a new prognostic tool. J Clin Oncol 13:765-782, 1995
4.Neufeld G, Kessler O, Vadasz Z, Gluzman-Poltorak Z.The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors.
Surg Oncol Clin N Am. 10:339-56, 2001
5. Halin C, Zardi L, Neri D. Antibody-based targeting of angiogenesis.
News Physiol Sci. 16:191-4, 2001
6. Weber WA, Haubner R, Vabuliene E, Kuhnast B, Wester HJ, Schwaiger M.Tumor angiogenesis targeting using imaging agents. Q J Nucl Med.45(2):179-82, 2001
7. de Groot FM, Damen EW, Scheeren HW.Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. Curr Med Chem. 8(9):1093-122, 2001.
8. Zetter, B. R. 1993. Adhesion molecules in tumor metastasis. Semin. Cancer Biol. 4:219-229.
9. Rice, G. E. and M. P. Bevilacqua.. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science (Wash. DC). 246:1303-1306, 1989.
10. Eliceiri BP, Cheresh DA. Adhesion events in angiogenesis. Curr Opin Cell Biol. 13, 563-568, 2001.
11. Walz, G., A. Aruffo, W. Kolanus, M. Bevilacqua and B. Seed. Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science (Wash. DC). 250:1132-1135, 1990.
12. Takada, A., K. Ohmori, N. Takahashi, K. Tsuyuoka, A. Yago, K. Zenita, A. Hasegawa and R. Kannagi. Adhesion of human cancer cells to vascular endothelium mediated by carbohydrate antigen, sialyl Lewis A. Biochem. Biophys. Res. Commun. 182:1288-1295,1991.
13. Dejana, E., I. Martin-Padura, D. Lauri, S. Bernasconi, M. R. Bani, A. Garofalo, R. Giavazzi, J. Magnani, A. Mantovani and S. Menard. Endothelial leukocyte adhesion molecule-1 -dependent adhesion of colon carcinoma cells to vascular endothelium is inhibited by an antibody to Lewis fucosylated type I carbohydrate chain. Lab. Invest. 66:324-330, 1992.
14. Iwai, K., H. Ishikura, M. Kaji, H. Sugiura, A. Ishizu, C. Takahashi, H. Kato, T. Tanabe and T. Yoshiki. Importance of E-selectin (ELAM-1) and sialyl Lewis a in the adhesion of pancreatic carcinoma cells to activated endothelium. Int. J. Cancer. 54:972-977, 1993.
15. Biancone L, Araki M, Araki K, Vassalli P, Stamenkovic I. Redirection of tumor metastasis by expression of E selectin in vivo. J Exp Med 183:581, 1996.
16. Karmann K, Hughes CC, Schechner J, Fanslow WC and Pober JS: CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A 92: 4342-4346, 1995.
17. Kluth B, Hess S, Engelman H, et al. Endothelial expression of CD40 in renal cell carcinoma. Cancer Res 57: 891-899, 1997.
18. van den Oord JJ, Maes A, Stass M et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Path 149: 1953- 1961,1996.
19.Bevilacqua, M. P. and R. M. Nelson.. Selectins J. Clin. Invest. 91:379-387, 1993.
20. Biancone L, Stamenkovic I, Cantalupi V, Boccellino M, De Martino A, Bussolino F, Camussi G. Expression of L-selectin ligands by transformed endothelial cells enhances T cell-mediated rejection. J Immunol 162: 5263-5269, 1999.
21. Beutler B, van Huffel C.Unraveling function in the TNF ligand and receptor families.
Science. 264(5159):667-8, 1994
22.Lagresle C, Mondiere P, Bella C, Krammer PH, Defrance T.Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas-mediated apoptosis.
J Exp Med. 1996 Apr 1;183(4):1377-88.
23. Hollenbaugh D, Mischel-Petty N, Edwards CP, Simon JC, Denfeld RW, Kiener PA, Aruffo A.Expression of functional CD40 by vascular endothelial cells. J Exp Med. 182:33-40, 1995
24. Pammer J, Plettenberg A, Weninger W, Diller B, Mildner M, Uthman A, Issing W, Sturzl M, Tschachler E.CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma.
Am J Pathol. 148(5):1387-96, 1996
25.Biancone L, Cantaluppi V, Boccellino M, Del Sorbo L, Russo S, Albini A, Stamenkovic I, Camussi G. Activation of CD40 favors the growth and vascularization of Kaposi’s sarcoma. J Immunol, 163(11):6201-8, 1999.
26. Defilippi P, Gismondi A, Santoni A, Tarone G. (1997) Signal Transduction by Integrins. Molecular Biology Intelligence Unit, Landes Bioscience, Austin Texas.
27. Giancotti FG and Ruoslahti E (1999) Integrin signaling. Science, 285, 1028-1032.
28. Eliceiri BP, Cheresh DA. (1999) The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 103, 1227-1230
29. Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yaremko B, Nechuta T, Varner J, Liu M, Smith, EM, Neustadt B, Presta M, Armstrong L. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 1, 61, 2232-2238.
30. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA. (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 6, 3056-3061.
31. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F.Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J.18:88, 1999.
32. Moro L,Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L, Tarone G, Defilippi P. (1998) EMBO J, 17, 6622-632.
33. Schwartz M and Baron V. (1999) Interactions between mitogenic stimuli, or, a thousand and one connections. Curr. Opin. Cell Biol., 11, 197-202.
34. Tetta C, Gianotti L, Cavaillon JM. Et al. Couplet plasma filtration adsorption in a rabbit model of endotoxic shock. Crit Care Med 28(5):1526-1533, 2000.

Parole Chiave

terapie loco-regionali; neoangiogenesi; chemioterapia; molecole di adesione; filtri; adsorbenti